Olverembatinib-Based Immunotherapy Shows Promise in Ph+ ALL

Company Peking University People’s Hospital Event Type Published Research (Peer-Reviewed, Retrospective Analysis) Modality BCR::ABL1 tyrosine-kinase inhibitor combined with antibody-based immunotherapy Asset Olverembatinib Target BCR::ABL1, including T315I and other resistant mutations Disease Area Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) Summary A retrospective comparison from Peking…